Skip to main content

CAR-T (Hematologic) Deal Benchmarks in Oncology

Median Upfront
$309M
Range: $172M - $438M
Total Deal Value
$2.0B
Range: $1.3B - $2.7B
Royalty Rate
12.5% - 20.4%
Tiered up to 24.4%
Dev Milestones
$414M
Range: $276M - $554M
Model Your Deal

Market Analysis

CAR-T (Hematologic) therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 car-t (hematologic) asset in oncology is $309M, with total deal values reaching $2.0B. Development milestones average $414M, while regulatory milestones contribute $662M.

The oncology car-t (hematologic) landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for car-t (hematologic) oncology deals range from 12.5% to 20.4% at the base tier, with tiered escalation reaching 16.5%-24.4% on blockbuster sales. Commercial milestones averaging $580M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a car-t (hematologic) oncology licensing deal?
Based on our analysis, Phase 2 car-t (hematologic) licensing deals in oncology average $309M in upfront payments, with a range of $172M to $438M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for car-t (hematologic) oncology transactions?
The median total deal value for Phase 2 car-t (hematologic) assets in oncology is $2.0B, ranging from $1.3B to $2.7B. This includes development milestones ($414M), regulatory milestones ($662M), and commercial milestones ($580M).
What royalty rates are standard for car-t (hematologic) deals in oncology?
Base royalty rates for car-t (hematologic) oncology transactions range from 12.5% to 20.4%, with tiered escalations reaching 16.5%-24.4% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in car-t (hematologic) oncology deals?
CAR-T (Hematologic) oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($414M) make up the largest share, followed by commercial milestones ($580M) and regulatory milestones ($662M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

CAR-T (Hematologic) in Hematology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included